Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AcTFirst: AAA817 ± ARPI vs standard of care in PSMA-positive mCRPC
jRCT2011250025Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Sep 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of actinium-225 PSMA-617 in prostate cancer (PCa) (3 arms), sponsored by Novartis. Primary endpoint: Radiographic progression-free survival (rPFS). Started Sep 2025; status: recruiting.
02
Drugs
actinium-225 PSMA-617
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2011250025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250025.